Evidence map›Paper›PMID 41959892›Full record

ReviewFrontiers in oncology2026

MYO1B in human disease: an actin-based motor linking membrane trafficking to oncogenic signaling, metastasis, and vascular aging.

Yunxin Li, Jiaqi Zhang, Xin Gao, Feilong Zhou, Tianyi Chen, Weijie Zhao, Xinhao Li, Yewei Zhang

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yunxin Li *General Surgery Department, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiaqi Zhang *General Surgery Department, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xin GaoGeneral Surgery Department, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Feilong ZhouGeneral Surgery Department, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Tianyi ChenGeneral Surgery Department, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Weijie ZhaoGeneral Surgery Department, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xinhao LiGeneral Surgery Department, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yewei ZhangGeneral Surgery Department, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myosins move along actin filaments by breaking down adenosine triphosphate (ATP) and using the energy it gives out. The superfamily presently has more than 35 classes. Mammals have the most frequent and well-preserved kind of myosin, which is class I (Myo1). People commonly group these isoforms by the morphology of their tails: long-tailed (like MYO1B, C, D), short-tailed, and tail-less. MYO1B is different from the others in that it has a lengthy tail but no second actin-binding domain. MYO1B is not evenly spread out in the body. Instead, it is mostly present near the edges of actin-rich plasma membranes and throughout the endolysosomal system, which includes early endosomes and lysosomes. It is vital for numerous bodily activities because it is located in several places, like the brain, heart, liver, and kidneys. This article brings together recent research on MYO1B's structure, signaling pathways, and disease-causing effects. Its goal is to be a complete source for future study.

Indexed as

actin cytoskeletonHNSCCmembrane traffickingmetastasisMYO1Boncogenic signaling

Identifiers

PMID41959892
PMCPMC13056627

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.